Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal
Novo Holdings, the controlling shareholder in Novo Nordisk Foundation, said Monday it has agreed to acquire Catalent in an all-cash transaction that values the pharmaceutical company at $16.5 billion, including debt,...To view the full article, register now.
Already a subscriber? Click here to view full article